Publications

Categories
Preclinical
April 10, 2021
AACR
Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
Von Rossum et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
January 15, 2021
ASCO GI
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs)
Pant et al.
Zanidatamab
November 22, 2019
ESMO Asia
Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor
Oh et al.
Zanidatamab Zovodotin
April 14, 2018 - April 18, 2018
AACR
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
Hamblett et al.